Bright Minds Biosciences Inc.DRUGNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank54
5Y CAGR-0.9%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-0.9%/yr
Long-term compound
Percentile
P54
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 18.32% |
| Q3 2025 | 77.73% |
| Q2 2025 | 5.02% |
| Q1 2025 | 145.18% |
| Q4 2024 | 151.26% |
| Q3 2024 | 173.41% |
| Q2 2024 | -638.84% |
| Q1 2024 | -91.42% |
| Q4 2023 | 12.30% |
| Q3 2023 | 3.87% |
| Q2 2023 | -24.86% |
| Q1 2023 | -4.21% |
| Q4 2022 | -42.56% |
| Q3 2022 | 23.88% |
| Q2 2022 | -45.20% |
| Q1 2022 | -2.65% |
| Q4 2021 | 74.14% |
| Q3 2021 | -18.46% |
| Q2 2021 | 159.17% |
| Q1 2021 | 196.19% |
| Q4 2020 | 19.20% |
| Q3 2020 | 1281.64% |
| Q2 2020 | 258.65% |
| Q1 2020 | -80.94% |
| Q4 2019 | 0.00% |